The drebrin/EB3 pathway drives invasive activity in prostate cancer
Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate can...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2017
|
| _version_ | 1826263220585758720 |
|---|---|
| author | Dart, A Worth, D Muir, G Chandra, A Morris, J McKee, C Verrill, C Bryant, R Gordon-Weeks, P |
| author_facet | Dart, A Worth, D Muir, G Chandra, A Morris, J McKee, C Verrill, C Bryant, R Gordon-Weeks, P |
| author_sort | Dart, A |
| collection | OXFORD |
| description | Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression. |
| first_indexed | 2024-03-06T19:48:16Z |
| format | Journal article |
| id | oxford-uuid:2313f444-5252-4448-8922-fadcb9426641 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:48:16Z |
| publishDate | 2017 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:2313f444-5252-4448-8922-fadcb94266412022-03-26T11:42:22ZThe drebrin/EB3 pathway drives invasive activity in prostate cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2313f444-5252-4448-8922-fadcb9426641EnglishSymplectic Elements at OxfordSpringer Nature2017Dart, AWorth, DMuir, GChandra, AMorris, JMcKee, CVerrill, CBryant, RGordon-Weeks, PProstate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression. |
| spellingShingle | Dart, A Worth, D Muir, G Chandra, A Morris, J McKee, C Verrill, C Bryant, R Gordon-Weeks, P The drebrin/EB3 pathway drives invasive activity in prostate cancer |
| title | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
| title_full | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
| title_fullStr | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
| title_full_unstemmed | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
| title_short | The drebrin/EB3 pathway drives invasive activity in prostate cancer |
| title_sort | drebrin eb3 pathway drives invasive activity in prostate cancer |
| work_keys_str_mv | AT darta thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT worthd thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT muirg thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT chandraa thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT morrisj thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT mckeec thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT verrillc thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT bryantr thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT gordonweeksp thedrebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT darta drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT worthd drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT muirg drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT chandraa drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT morrisj drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT mckeec drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT verrillc drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT bryantr drebrineb3pathwaydrivesinvasiveactivityinprostatecancer AT gordonweeksp drebrineb3pathwaydrivesinvasiveactivityinprostatecancer |